Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer.

Lung cancer (Amsterdam, Netherlands) - 1 Apr 2018

Song Zhengbo, Cheng Guoping, Xu Chunwei, Wang Wenxian, Shao Yang, Zhang Yiping

Abstract excerpt

BACKGROUND: Mutations in polymerase ε (POLE), a DNA polymerase involved in DNA replication and repair, have been investigated in endometrial cancers and response to programmed cell death protein 1 (PD-1)/PD-1 ligand (PD-L1) immunotherapy. However, the frequency of POLE gene mutation in patients with non-small cell lung cancer (NSCLC) has not been reported. MATERIALS AND METHODS: We assessed POLE mutation in 319...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to B7-H1 Antigen
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Polymerase II

Share to High-Throughput Nucleotide Sequencing

Share to Immunohistochemistry

Share to Lymphocytes, Tumor-Infiltrating

Share to Poly-ADP-Ribose Binding Proteins

Share to Survival Analysis

Source

Identifiers

PMID: 29572003
DOI: 10.1016/j.lungcan.2018.02.004

Genes

POLE
MLH1
MSH2
MSH6
PMS2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer.PMID 29572003Read ↗

Favorable outcome of patients with lung adenocarcinoma harboring POLE mutations and expressing high PD-L1Semantic proximity Read ↗

Mutant POLQ and POLZ/REV3L DNA polymerases may contribute to the favorable survival of patients with tumors with POLE mutations outside the exonuclease domain.Semantic proximity Read ↗

The game-changing impact of POLE mutations in oncology—a review from a gynecologic oncology perspectiveSemantic proximity Read ↗

Phenotypic POLE Variant Classification Identifies Patients Who May Have Favorable Prognosis and Benefit from Immunotherapy.Semantic proximity Read ↗

Mutant POLQ and POLZ/REV3L DNA polymerases may contribute to favorable survival of tumors with POLE mutations outside the exonuclease domainSemantic proximity Read ↗

Tumor Mutational Burden Guides Therapy in a Treatment Refractory POLE-Mutant Uterine Carcinosarcoma.Semantic proximity Read ↗

Pathogenic POLE-Mutated Endometrial Carcinomas With a Nonultramutated Genome.Semantic proximity Read ↗

Distinct mutational profile and immune microenvironment in microsatellite-unstable and POLE-mutated tumorsSemantic proximity Read ↗

Integrating POLE/POLD1 mutated for immunotherapy treatment planning of advanced stage non-small cell lung cancer.Semantic proximity Read ↗

Polymerase ɛ (<scp><i>POLE</i></scp>) mutations in endometrial cancer: Clinical outcomes and implications for <scp>L</scp>ynch syndrome testingSemantic proximity Read ↗

Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers.Semantic proximity Read ↗

Frequent POLE-driven hypermutation in ovarian endometrioid cancer revealed by mutational signatures in RNA sequencing.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.